肿瘤学和免疫学流式细胞仪市场——全球行业规模、份额、趋势、竞争、机会和预测，按类型、按技术、按产品、按应用、按最终用户、按地区和竞争进行细分，2020 年至 2030 年

2024 年全球流式细胞仪在肿瘤学和免疫学市场的规模为 34.1 亿美元，预计到 2030 年将达到 54.7 亿美元，预测期内的复合年增长率为 8.19%。流式细胞仪在癌症和免疫学研究中的日益普及，以及先进流式细胞仪的不断发展，推动了市场的成长。随着癌症成为全球主要死因之一，免疫肿瘤学作为一门重要学科日益受到重视，对高精度诊断和监测工具的需求日益增长。流式细胞仪已成为评估各种样本中细胞特性、免疫标记和肿瘤抗原不可或缺的工具。下一代流式细胞仪工具与治疗监测和诊断的结合，尤其是在免疫疗法和个人化治疗的临床试验中，正在推动全球采用。再加上不断增加的研究投入和全球对早期疾病检测的重视，这些因素共同扩大了流式细胞仪在肿瘤学和免疫学中的应用范围和范围。

关键市场驱动因素

癌症发生率上升推动诊断需求

主要市场挑战

高成本和操作复杂性

主要市场趋势

与人工智慧和机器学习的集成

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球肿瘤学与免疫学流式细胞仪市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型（免疫学、肿瘤学）
  • 依技术分类（基于细胞的流式细胞仪、基于珠子的流式细胞仪）
  • 依产品提供（试剂、仪器及耗材软体）
  • 按应用（转化研究、临床研究）
  • 按最终用户（医院、诊断实验室和参考实验室、製药和生物技术公司、学术研究机构、合约研究组织等）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司分类（2024）
• 市场地图
  • 按类型
  • 依技术
  • 透过提供
  • 按应用
  • 按最终用户
  • 按地区

第六章：北美肿瘤学与免疫学流式细胞仪市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肿瘤学与免疫学流式细胞仪市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区肿瘤学与免疫学流式细胞仪市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲

第九章：南美洲肿瘤学和免疫学流式细胞仪市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲肿瘤学和免疫学流式细胞仪市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 阿联酋
  • 沙乌地阿拉伯
  • 南非

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品/服务的威胁

第 14 章：肿瘤学和免疫学流式细胞仪市场的全球市场：SWOT 分析

第 15 章：竞争格局

• Danaher Corporation
• Merck KGaA
• Miltenyi Biotec
• Neo-Genomics Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Cell Signaling Technology, Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• DiaSorin SpA
• OPKO Health, Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Flow Cytometry in Oncology and Immunology Market was valued at USD 3.41 billion in 2024 and is projected to reach USD 5.47 billion by 2030, growing at a CAGR of 8.19% during the forecast period. Market growth is propelled by the increasing utility of flow cytometry in cancer and immunology research, alongside the evolution of advanced flow cytometers. With cancer ranking among the leading causes of death globally, and immuno-oncology gaining ground as a crucial discipline, there is rising demand for high-precision diagnostic and monitoring tools. Flow cytometry has become indispensable in evaluating cell characteristics, immune markers, and tumor antigens across various sample types. The integration of next-generation flow cytometry tools with therapeutic monitoring and diagnostics, especially in clinical trials for immunotherapies and personalized treatments, is boosting global adoption. Combined with rising research investments and the global emphasis on early disease detection, these factors are collectively expanding the reach and application of flow cytometry in both oncology and immunology.

Key Market Drivers

Rising Cancer Incidence Driving Diagnostic Demand

The growing global cancer burden is a key driver for the adoption of flow cytometry in oncology diagnostics. This technique is critical for diagnosing and monitoring blood cancers like leukemia and lymphoma, enabling precise cellular analysis and biomarker identification. As per WHO, cancer accounted for nearly 10 million deaths in 2020, and GLOBOCAN estimates that new cancer cases will surge past 28 million by 2040. Flow cytometry is also instrumental in detecting minimal residual disease (MRD) and supporting treatment decisions. With increasing adoption of immunotherapies and personalized oncology treatments, flow cytometry's role in immune profiling and response monitoring is expanding. In support, organizations like the U.S. National Cancer Institute have committed billions to precision medicine and diagnostics infrastructure, fostering widespread implementation. These efforts underscore flow cytometry's importance in the future of cancer diagnosis and treatment.

Key Market Challenges

High Cost and Operational Complexity

Despite its clinical and research value, flow cytometry adoption is hindered by high operational and capital expenses. The cost of acquiring high-end instruments, software, and consumables is substantial, making it challenging for institutions in developing regions to invest. Additionally, flow cytometry requires technical expertise for calibration, analysis, and interpretation-skills that are often limited in resource-constrained settings. Complex data interpretation can introduce variability and errors, further complicating implementation. The lack of infrastructure and diagnostic capacity in many low- and middle-income countries reinforces disparities in access to this technology. According to WHO data, these regions have significantly fewer diagnostic labs per capita, highlighting access challenges. Addressing these cost and skill barriers is essential to ensuring broader and more equitable utilization of flow cytometry worldwide.

Key Market Trends

Integration with Artificial Intelligence and Machine Learning

A transformative trend in the flow cytometry space is the integration of artificial intelligence (AI) and machine learning (ML) into data processing workflows. Traditional manual gating and analysis can be time-consuming and prone to human error. AI and ML technologies now streamline these processes by automating gating, improving pattern recognition, and extracting high-dimensional insights from complex datasets. In oncology, ML algorithms are being applied to predict treatment outcomes using immune signatures from flow cytometry data. In immunology, these tools aid in identifying rare cell subsets and monitoring immune dynamics with high precision. Global research initiatives like NIH's Bridge2AI and the EU's Horizon Europe are actively funding the incorporation of AI into diagnostics, including flow cytometry. This convergence of data science with laboratory medicine is poised to elevate accuracy, reproducibility, and clinical utility, marking a pivotal evolution in how flow cytometry is applied in healthcare.

Key Market Players

• Danaher Corporation
• Merck KGaA
• Miltenyi Biotec
• Neo-Genomics Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Cell Signaling Technology, Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• DiaSorin S.p.A
• OPKO Health, Inc.

Report Scope:

In this report, the Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Flow Cytometry in Oncology and Immunology Market, By Type:

• Immunology
• Oncology

Flow Cytometry in Oncology and Immunology Market, By Technology:

• Cell-based flow cytometry
• Bead-based flow cytometry

Flow Cytometry in Oncology and Immunology Market, By Offering:

• Reagents
• Instruments
• Consumables
• Software

Flow Cytometry in Oncology and Immunology Market, By Application:

• Translational Research
• Clinical Research

Flow Cytometry in Oncology and Immunology Market, By End User:

• Hospitals
• Diagnostic Laboratories
• Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations
• Others

Flow Cytometry in Oncology and Immunology Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Flow Cytometry in Oncology and Immunology Market.

Available Customizations:

Global Flow Cytometry in Oncology and Immunology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Cytometry in Oncology and Immunology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Immunology, Oncology)
  • 5.2.2. By Technology (Cell-based flow cytometry, Bead-based flow cytometry)
  • 5.2.3. By Offering (Reagents, Instruments, and Consumables Software)
  • 5.2.4. By Application (Translational Research, Clinical Research)
  • 5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others)
  • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)
  • 5.2.7. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Type
  • 5.3.2. By Technology
  • 5.3.3. By Offering
  • 5.3.4. By Application
  • 5.3.5. By End User
  • 5.3.6. By Region

6. North America Flow Cytometry in Oncology and Immunology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Technology
  • 6.2.3. By Offering
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Offering
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Offering
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Offering
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Flow Cytometry in Oncology and Immunology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Technology
  • 7.2.3. By Offering
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Offering
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Offering
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Offering
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Offering
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Offering
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia-Pacific Flow Cytometry in Oncology and Immunology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Technology
  • 8.2.3. By Offering
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Offering
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. Japan Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Offering
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. India Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Offering
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Offering
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Offering
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. South America Flow Cytometry in Oncology and Immunology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Technology
  • 9.2.3. By Offering
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Offering
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Offering
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Offering
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. Middle East and Africa Flow Cytometry in Oncology and Immunology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Technology
  • 10.2.3. By Offering
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Flow Cytometry in Oncology and Immunology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Offering
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Offering
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Offering
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challanges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products/Services

14. Global Flow Cytometry in Oncology and Immunology Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Miltenyi Biotec
• 15.4. Neo-Genomics Laboratories, Inc.
• 15.5. Thermo Fisher Scientific Inc.
• 15.6. Cell Signaling Technology, Inc.
• 15.7. Becton, Dickinson and Company
• 15.8. Agilent Technologies, Inc.
• 15.9. DiaSorin S.p.A
• 15.10. OPKO Health, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer